Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

About NXL104

NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (penicillins, cephalosporins, carbopenems) mediated by beta-lactamase enzymes.

NXL104 is a significant advance, as it is able to inhibit a broader range of beta-lactamases than currently marketed inhibitors. Its spectrum includes class A (including ESBL and KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae and Pseudomonas.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... The Prix Galien USA committee recognized excellence in scientific ... during the fifth annual Prix Galien Awards Gala. The Pro ... for best biotechnology product and best pharmaceutical agent were presented ... in New York City.   The Prix Galien ...
... AdvaMed 2011: The MedTech Conference ... exhibitors including Abbott, Abiomed, B. Braun Medical, Baxter ... KCI, and MIT MEDRC in Innovation Alley, a ... technologies. Three sector meet-ups focused on orthopedic, wound ...
Cached Medicine Technology:Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony 2AdvaMed 2011: The MedTech Conference Closing Day Features Life Changing Innovation, Policymaker Addresses 2
(Date:7/12/2014)... Angeles, CA (PRWEB) July 12, 2014 ... buyer power score of 4.1 out of 5. ... market that have been underpinning buyer negotiation power ... IBISWorld procurement analyst Anna Son, “during the period, ... with rising costs associated with new product development, ...
(Date:7/11/2014)... 12, 2014 Recently, MagicQuinceaneraDresses.com, the popular ... new collection of 2014 Quinceanera dresses . The ... want to look fashionable without paying a large amount ... up to 57% off. , The company’s online shop ... get amazing special occasion outfits. In addition to exquisite ...
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
(Date:7/11/2014)... 2014 As part of its ... LLP has been closely monitoring the ongoing meeting ... Obstetrics and Gynecology Devices Panel, which has ... cancer risks associated with the use of power ... a report published by Dow Jones Business News, ...
Breaking Medicine News(10 mins):Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... So what do you get for the nut,that has ... the Ask Doctor Chuck talking therapy doll?, You can ... by providing,someone who needs it, their own personal and portable ... kook in line, which could,earn you the undying gratitude of ...
... Higher-risk Myelodysplastic Syndromes (MDS), Thalidomide in Multiple ... ... Pharmion Corporation,(Nasdaq: PHRM ) reported today that data from ... will,be presented at the American Society of Hematology,s (ASH) 49th Annual,Meeting ...
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... More in ... 2008, - Late-Stage Pipeline Offers Promising Outlook; 6 Launches Expected by end ... of 2011, ... in Unprecedented 44 New Molecules Under Development, - Transformation Efforts to Focus ...
... StemCor Systems, Inc., a,medical device company developing ... it has acquired U.S. Patent 6,849,051,"Devices And ... associated,know-how from USPure Sciences, LLC. The patent ... from bone cavities. The concept and,technologies are ...
... EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: EPCT) today ... a company overview at the New York Society,of ... Pharma,Conference on December 12, 2007 at 4:05 p.m. ... NYSSA,s headquarters at 1177 Avenue of the Americas ...
Cached Medicine News:Health News:The Cure for Holiday Stress 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 3Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 4Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 5Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 6Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 7Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 8Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 9Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 10Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 3Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 4Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 5Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 6Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 7Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 8Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 9Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 10Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 11Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 12Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 13Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 14Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 2Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 3Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 2Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 3
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Posterior Capsule Polisher, 23 g., 30 angle small gauge with roughened tip, open end port. Overall length 16 mm. 5/box....
Irrigating Cystotome, formed, 27 g., short 8 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: